Search

Your search keyword '"Horiguchi, Norio"' showing total 197 results
Start Over Author "Horiguchi, Norio" Publication Type Academic Journals
197 results on '"Horiguchi, Norio"'

3. Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin

Author

Sato, Ken, Naganuma, Atsushi, Nagashima, Tamon, Hoshino, Takashi, Uehara, Daisuke, Arai, Yousuke, Horiuchi, Katsuhiko, Yuasa, Kazuhisa, Takayama, Hisashi, Arai, Hirotaka, Hatanaka, Takeshi, Ohyama, Tatsuya, Tahara, Hiroki, Sohara, Naondo, Kobayashi, Takeshi, Horiguchi, Norio, Yamazaki, Yuichi, Kakizaki, Satoru, Kusano, Motoyasu, Yamada, Masanobu, Murase, Takayo, and Nakamura, Takashi

Published
2018
Full Text
View/download PDF

17. HGF ameliorates a high-fat diet-induced fatty liver

Author

Kosone, Takashi, Takagi, Hitoshi, Horiguchi, Norio, Ariyama, Yasuyo, Otsuka, Toshiyuki, Sohara, Naondo, Kakizaki, Satoru, Sato, Ken, and Mori, Masatomo

Subjects
Liver cells -- Research, Endothelial growth factors -- Research, Apolipoproteins -- Research, Liver diseases -- Research, Cell research, Biological sciences
Abstract

Hepatocyte growth factor (HGF) has various effects especially on epithelial cells. However, the precise role of HGF on lipogenesis is still not fully understood. A high-fat diet was administered to HGF transgenic mice and wild-type control mice in vivo. Furthermore, recombinant human HGF (rhHGF) was administered to HepG2 cell line in vitro. We performed an analysis regarding the factors relating to lipid metabolism. An overexpression of HGF dramatically ameliorates a high-fat diet-induced fatty liver. HGF transgenic mice showed an apparently reduced lipid accumulation in the liver. The activation of microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) accompanying higher triglyceride levels in the serum were found in HGF transgenic mice on a normal diet. Interestingly, this upregulation of the MTP activation became more apparent in the high-fat diet. In addition, the administration of rhHGF stimulated MTP and ApoB expression while reducing reduced the intracellular lipid content in HepG2 cell line. However, this induction of MTP and ApoB by HGF was clearly inhibited by PD98059 (MAPK inhibitor). In conclusion, the data presented in this study indicated that HGF ameliorates a high-tat diet-induced fatty liver via the activation of MTP and ApoB. hepatocyte growth factor: fatty liver; microsomal triglyceride transfer protein; apolipoprotein B doi:10.1152/ajpgi.00021.2007

Published
2007

22. Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy.

Author

Sato, Ken, Yamazaki, Yuichi, Kanayama, Yuki, Uehara, Daisuke, Tojima, Hiroki, Suga, Takayoshi, Kakizaki, Satoru, Sohara, Naondo, Horiguchi, Norio, and Uraoka, Toshio

Subjects
CHRONIC hepatitis C, HEPATITIS C, JAPANESE people, ANTIVIRAL agents, TEENAGERS
Abstract

Three Japanese adolescents with chronic hepatitis C were treated by direct‐acting antivirals (DAAs). No adverse events or laboratory abnormalities were observed during and after DAA therapy, and a sustained virological response was achieved in all cases. The emotional functioning of the patients and their mothers were improved after DAA therapy. Key Clinical Message: The efficacy/safety of therapy with direct‐acting antivirals for chronic hepatitis C in Japanese adolescents were favorable and the improvement of emotional functioning of them and their mothers by viral eradication was observed in all cases. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Integrative roles of transforming growth factor-α in the cytoprotection mechanisms of gastric mucosal injury

Author

Yoneda Masashi, Sato Ken, Horiguchi Norio, Sohara Naondo, Kakizaki Satoru, Takagi Hitoshi, Kosone Takashi, Takeuchi Toshiyuki, and Mori Masatomo

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Transforming growth factor α (TGFα) protects against gastric mucosal injury and facilitates wound healing. However, its overexpression is known to induce hypertrophic gastropathy resembling Menetrier's disease in transgenic (TG) mice on an FVB background, as one of the authors reported previously. We studied another TGFα-expressing mouse line on a CD1 background, whose gastric mucosa appears normal. Since this TG mouse had a strong resistance to ethanol-induced gastric injury, we considered the long-term effect of TGFα on several gastric protection mechanisms. Methods TGFα-expressing transgenic (TG) mouse lines bearing human TGFα cDNA under the control of the mouse metallothionein gene I promoter were generated on a CD1 mouse background, and analyzed their ethanol injury-resistant phenotypes produced by TGFα. Results In the TG mucosa, blood flow was well maintained after ethanol injury. Further, neural and inducible types of NO synthases were consistently and widely expressed in the TG mucosa, compared with the limited distribution of neural type NO synthase in the luminal pit region of the wild-type (WT) mucosa. COX-2 and its upstream transcription factor NfkB were constitutively elevated in the TG mucosa even before ethanol administration, whereas they were induced in the same region of the WT mucosa only after ethanol injury. Two anti-apoptotic proteins, HSP70 and Bcl-2, were upregulated in the TG mucosa even before ethanol administration, while they were not expressed in the WT mucosa before the injury. Furthermore, pro-caspase 3 activation was inhibited in the TG mucosa, while it was converted to the active form in the WT mucosa following ethanol administration. Conclusion We conclude that TGFα maintains the gastric mucosal defense against gastric injury by integrating other cytoprotective mechanisms.

Published
2006
Full Text
View/download PDF

47. Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.

Author

Yamazaki, Yuichi, Naganuma, Atsushi, Arai, Yosuke, Takeuchi, Suguru, Kobayashi, Takeshi, Takakusagi, Satoshi, Hatanaka, Takeshi, Hoshino, Takashi, Namikawa, Masashi, Hashizume, Hiroaki, Takizawa, Daichi, Ohyama, Tatsuya, Suzuki, Hideyuki, Horiguchi, Norio, Takagi, Hitoshi, Sato, Ken, Kakizaki, Satoru, Kusano, Motoyasu, Nagashima, Shigeo, and Takahashi, Masaharu

Subjects
HEPATITIS E, IMMUNOSUPPRESSION, CANCER chemotherapy, HOSPITAL care, INFECTIOUS disease transmission, THERAPEUTICS
Abstract

Aim To evaluate the clinical and virological features of acute hepatitis E (AH-E) in Gunma prefecture and focus on the hepatitis E virus (HEV) infection in immunocompromised patients. Methods A total of 30 patients with AH-E diagnosed at our Gunma University Hospital, and located in 3-39-15 Showa-machi, Maebashi, Gunma 371-8511 Japan, and its affiliated hospitals from 2004 to 2015, were studied. We evaluated the detailed medical histories, laboratory examinations and virological features of these participants. Results Of the 30 patients, 21 patients were men, with a median age of 61 years. Three of these patients had a history of recent oversea travel. A total of 14 patients had eaten raw or undercooked meat/viscera from animals, and two patients had contracted transfusion-transmitted AH-E. Eight patients were immunocompromised, including those with hematological disease, cancer receiving systemic chemotherapy and kidney transplant or connective tissue disease undergoing immunosuppressive medications. The alanine aminotransferase and total bilirubin levels were more significantly reduced in these immunocompromised patients than in the non-immunocompromised patients. Severe thrombocytopenia, an extra-hepatic manifestation of AH-E, occurred in one case. Among the 22 HEV strains whose subgenotype was determined, two were imported strains (1a and 1f), and 11 strains formed four distinct phylogenetic clusters within subgenotype 3b. The remaining nine strains differed from each other by 9.8-22.4%, and were classified into four subgenotypes (3a, 3b, 3e and 3f). Conclusion Markedly divergent HEV strains (3a, 3b, 3e and 3f) were found to circulate in Gunma. Although immunosuppression appears to play a crucial role in establishing chronic sequels, AH-E in eight immunocompromised patients, including transfusion-transmitted HEV infection in two patients, did not become chronic. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Sa1339 Assessment of Esophago-Gastric Junction Morphology and Barrier Function by Combined High Resolution Manometry and Endoscopy for Evaluating a Risk of Gastroesophageal Reflux Disease

Author

Kuribayashi, Shiko, Hosaka, Hiroko, Kawada, Akiyo, Akiyama, Junichi, Fukai, Yasumori, Kobayashi, Takeshi, Nakayama, Tetsuo, Tomizawa, Taku, Yasuoka, Hidetoshi, Ohyama, Tatsuya, Mizuide, Masafumi, Horiguchi, Norio, Yamazaki, Yuichi, Shimoyama, Yasuyuki, Sato, Ken, Kakizaki, Satoru, Kawamura, Osamu, Yamada, Masanobu, and Kusano, Motoyasu

Published
2016
Full Text
View/download PDF

49. A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia.

Author

Hosonuma, Kenichi, Sato, Ken, Yamazaki, Yuichi, Yanagisawa, Masatoshi, Hashizume, Hiroaki, Horiguchi, Norio, Kakizaki, Satoru, Kusano, Motoyasu, and Yamada, Masanobu

Subjects
RESPIRATORY therapy, URSODEOXYCHOLIC acid, CIRRHOSIS of the liver, DYSLIPIDEMIA, COMBINATION drug therapy, PATIENTS, THERAPEUTICS
Abstract

OBJECTIVES:The aim of this study was to assess the long-term prognosis, efficacy, and safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for primary biliary cirrhosis (PBC) patients exhibiting dyslipidemia.METHODS:We performed a prospective, randomized, controlled, multicenter study to compare the long-term clinical results between combination therapy and UDCA monotherapy for patients refractory to UDCA monotherapy. Twenty-seven consecutive PBC patients were enrolled.RESULTS:The median treatment period in the UDCA and UDCA+BF groups was 107 and 110 months, respectively. The serum alkaline phosphatase (ALP) levels and the Mayo risk score in the combination therapy group (mean 290 IU/l and 0.91, respectively) were significantly lower than those in the UDCA monotherapy group (mean 461 IU/l and 1.42, respectively) at 8 years after the beginning of the study (P<0.05). The serum creatinine levels in the combination therapy group (mean 0.94 mg/dl) were significantly higher than those in the UDCA monotherapy group (mean 0.56 mg/dl) at 8 years after the beginning of the study (P<0.05). However, the survival rate was not significantly different between the groups. We observed dose reduction or discontinuation of the administration of BF, but not UDCA, due to renal dysfunction or muscle pain.CONCLUSIONS:Long-term combination therapy significantly improved the serum ALP levels and the Mayo risk score. However, the survival rate was not significantly different between the groups. In addition, long-term combination therapy significantly increased the serum creatinine levels. We should pay close attention to adverse events during this long-term combination therapy. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results